限时进食对糖尿病前期或2型糖尿病患者血糖代谢的影响:随机对照试验的系统综述与荟萃分析
该系统综述与荟萃分析纳入10项RCT共599例糖尿病前期或2型糖尿病患者,评估限时进食(TRE,进食窗口≤12小时)对血糖代谢指标的影响。中等确定性证据表明TRE降低空腹血糖但不降低HbA1c;亚组分析显示TRE改善糖尿病前期患者的HbA1c和空腹血糖,并改善2型糖尿病患者的空腹血糖。
要点
- TRE降低空腹血糖(-0.30 mmol/l,95%CI -0.53至-0.07),但对总体HbA1c无显著影响。
- 糖尿病前期患者HbA1c降低0.93 mmol/mol(95%CI -1.70至-0.17),2型糖尿病患者无显著变化。
- TRE降低体重1.6 kg(95%CI -2.2至-1.0),对胰岛素敏感性等指标结论不确定。
核心结论
- 中等确定性证据表明TRE降低空腹血糖但不降低HbA1c,亚组分析显示糖尿病前期患者HbA1c和空腹血糖均改善,2型糖尿病患者仅空腹血糖改善。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和CENTRAL从建库至2025年8月5日,纳入10项RCT共599例成人糖尿病前期或2型糖尿病患者。
- 纳入标准为TRE(进食窗口≤12小时)对比非时间限制对照饮食,干预时长≥2周,报告血糖代谢和调节指标。
主要发现
- 汇总分析显示TRE对HbA1c无总体效应(-3.33 mmol/mol;95%CI -6.87至0.20;p=0.06,中等确定性)。
- 亚组分析显示糖尿病前期患者HbA1c降低0.93 mmol/mol(95%CI -1.70至-0.17;p=0.02),2型糖尿病患者无显著变化(-4.68 mmol/mol;95%CI -10.08至0.72;p=0.09)。
- TRE降低汇总空腹血糖(-0.30 mmol/l;95%CI -0.53至-0.07;p<0.01,中等确定性),糖尿病前期亚组降低0.14 mmol/l(95%CI -0.27至-0.01;p=0.03),2型糖尿病亚组降低0.48 mmol/l(95%CI -0.78至-0.17;p<0.01)。
- TRE降低体重1.6 kg(95%CI -2.2至-1.0;p<0.001)。
- TRE对胰岛素敏感性、β细胞功能和连续血糖监测指标的影响结论不确定。
关键数值与推荐
- 糖尿病前期定义:空腹血糖5.6-6.9 mmol/l或HbA1c 39-47 mmol/mol(5.7-6.4%)。
- 2型糖尿病定义:空腹血糖≥7 mmol/l或HbA1c≥48 mmol/mol(6.5%)。
- TRE定义:进食窗口≤12小时,纳入研究的进食窗口为每天4至10小时。
临床怎么用
- TRE可作为糖尿病前期患者改善HbA1c和空腹血糖的饮食干预选择之一。
- 对于2型糖尿病患者,TRE有助于降低空腹血糖和体重,但对HbA1c的改善证据不足。
局限性
- 部分纳入研究置信区间宽,可能因样本量小导致不精确性,限制了证据强度。
- 研究平均时长4个月,长期效果未知,需大规模研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: This systematic review and meta-analysis aimed to investigate the effects of time-restricted eating (TRE) on glucose metabolism and regulation in individuals with prediabetes (fasting blood glucose of 5.6-6.9 mmol/l or HbA1c of 39-47 mmol/mol [5.7-6.4%]) or type 2 diabetes (fasting blood glucose ≥7 mmol/l or HbA1c ≥48 mmol/mol [6.5%]). METHODS: A literature search was performed in MEDLINE, Embase and CENTRAL from inception to 5 August 2025. Moreover, forward and backward citation searches were performed. Eligible studies were RCTs in adults with prediabetes or type 2 diabetes, lasting ≥2 weeks, reporting markers of glucose metabolism and regulation, comparing TRE (≤12 h eating window) with a non-time-restricted control diet. Studies involving pregnancy, other fasting regimens, or non-peer-reviewed publications were excluded. Data were pooled as weighted mean differences with 95% CIs using random-effects generic inverse variance models in Cochrane Review Manager Web, and results are presented as forest plots. The certainty of evidence was defined using Grading of Recommendations, Assessment, Development and Evaluations methodology, and risk of bias was estimated by using the Revised Cochrane risk-of-bias tool for randomised trials (RoB 2). RESULTS: Out of 2043 records identified through the database search, as well as 1249 from forward and backward citation searches, ten RCTs including 599 participants were included. The mean length of the studies was 4 months, and the eating windows ranged from 4 to 10 h per day. The pooled meta-analysis showed no overall effect of TRE on HbA1c (-3.33 mmol/mol; 95% CI -6.87, 0.20 (-0.30% points; -0.63, 0.02); p=0.06, moderate certainty). Nevertheless, following stratification by subgroups, TRE resulted in a reduction in HbA1c of 0.93 mmol/mol (-1.70, -0.17 [-0.09% points; -0.16, -0.02]; p=0.02) in individuals with prediabetes but not in individuals with type 2 diabetes (-4.68 mmol/mol; -10.08, 0.72 (-0.43% points; -0.92, 0.07); p=0.09). TRE reduced fasting blood glucose in the pooled analysis (-0.30 mmol/l; -0.53, -0.07; p<0.01, moderate certainty) as well as in the subgroup analyses in individuals with prediabetes (-0.14 mmol/l; -0.27, -0.01; p=0.03) and with type 2 diabetes (-0.48 mmol/l; -0.78, -0.17; p<0.01). Moreover, TRE lowered body weight by 1.6 kg (-2.2, -1.0; p<0.001) in the pooled analysis. The evidence was limited by imprecision arising from wide confidence intervals in some of the included studies, which may be due to small sample sizes. Lastly, the effects of TRE on markers of insulin sensitivity, beta cell function and continuous glucose monitoring measurements were inconclusive. CONCLUSIONS/INTERPRETATION: Moderate-certainty evidence indicates that TRE reduces fasting blood glucose but not HbA1c. The subgroup analyses revealed that TRE improved HbA1c and fasting glucose in individuals with prediabetes and improved fasting glucose in individuals with type 2 diabetes. Future large-scale studies should investigate long-term effects of TRE in prevention and treatment of type 2 diabetes. TRIAL REGISTRATION: PROSPERO CRD42024523591 FUNDING: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. Three authors (JS, A-DT, THA) are employed at Steno Diabetes Center Copenhagen, a public hospital and research institution under the Capital Region of Denmark, partly funded by a grant from the Novo Nordisk Foundation.
引用
- Viple F, Pedersen SS, Andersen TH, et al. Effects of time-restricted eating on markers of glucose metabolism and regulation in individuals with prediabetes or type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2026. PMID: 42507108. doi:10.1007/s00125-026-06792-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。